New InsulinGlargine 300Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial

Randomized participants (n = 811) had amean (SD) HbA1c of 8.24% (0.82) and BMI of 34.8 kg/m (6.4). Glycemic control improved similarly with both basal insulins; least squares mean (SD) reduction from baseline was 20.57% (0.09) for Gla-300 and20.56% (0.09) for Gla-100 (mean difference20.01% [95% CI20.14 to 0.12]), with 10% higher dose of Gla-300. Less nocturnal confirmed (£3.9 mmol/L [£70 mg/dL]) or severe hypoglycemia was observed with Gla-300 from week 9 to month 6 (relative risk 0.77 [95% CI 0.61–0.99]; P = 0.038) and during the first 8 weeks. Fewer nocturnal and any time (24 h) hypoglycemic events were reported during the entire 6-month period. Weight gain was lower with Gla-300 than with Gla-100 (P = 0.015). No between-treatment differences in safety parameters were identified.